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Background: Formation of biofilm is known to enhance the virulence of methicillin-resistance Staphylococcus
aureus (MRSA), which is associated with persistent infections in hospital settings. The biofilm layer essentially forms
a protective barrier encapsulating the bacterial colony and thus reduces the effectiveness of chemotherapeutics. We
have isolated 9EA-FC-B bioactive fraction from Acalypha wilkesiana Müll. Arg. that reverses ampicillin resistant in
MRSA through inhibition of the antibiotic resistant protein, penicillin-binding protein 2a (PBP2a). In this study, we
aimed to investigate the effects of 9EA-FC-B on MRSA biofilm forming capacity.
Methods: Inhibition of biofilm production and microtiter attachment assays were employed to study the
anti-biofilm activity of 9EA-FC-B, while latex agglutination test was performed to investigate the effect on PBP2a in
the biofilm matrix. We also attempted to characterise the chemical components of the fraction using high
performance liquid chromatography (HPLC) and phytochemical analysis.
Results: Fraction 9EA-FC-B and ampicillin exhibited similar inhibitory effect on MRSA’s biofilm production at their
respective minimum inhibitory concentrations (81.56% vs 84.49%, respectively). However, the test fraction was more
effective in suppressing cell surface attachment (90.85%) compared to ampicillin (37.8%). Interestingly, ampicillin
enhanced the level PBP2a and in the contrary 9EA-FC-B attenuated the production of the resistant protein in the
bioflim matrix. HPLC and phytochemical analysis revealed that 9EA-FC-B fraction is a complex mixture containing
tannins, saponins, sterol/steroids, and glycosides.
Conclusions: Bioactive fraction 9EA-FC-B inhibited the production of MRSA biofilm by preventing the initial
cell-surface attachment and reducing the amount PBP2a in the matrix. PBP2a found in the biofilm matrix is believed
to have a role in the development of virulence in MRSA.
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The biofilm formation of MRSA has been attributed as a
major factor for nosocomial infections [1] and treatments
for these infections are further complicated by the presence
of other virulent factors such as toxic production and host
immune evasion ability [2]. A distinctive characteristic of
biofilm or glycocalyx barrier is its recalcitrant to antimicro-
bial agents. The biofilm forms a physiological wall protecting* Correspondence: Kang-Nee.Ting@nottingham.edu.my
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unless otherwise stated.bacterial cells from any fluctuations of the environment in-
cluding any potential antibacterial agents [3,4]. Biofilm pro-
tected bacterial cells present a different mode of growth
compared to planktonic cells, and the peculiarity of the
mode of growth contributes to manifestation of antibiotic
resistance. Due to this reason, treatment for biofilm-related
infection becomes increasingly challenging, leading eventu-
ally to chronic device related infections which are often diffi-
cult to treat [3,5]. Most of the time, removal of the infected
devices is the only clinical solution and the affected patients
are succumbed to increased trauma as a result [6].al. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Santiago et al. BMC Complementary and Alternative Medicine  (2015) 15:79 Page 2 of 7Biofilm formation in MRSA was previously reported to
be mediated by the resistant protein, PBP2a, which is ac-
quired and expressed in MRSA to overcome antimicro-
bial action of beta-lactam antibiotics [7]. It was
hypothesized that PBP2a facilitates cell-cell interactions
in the formation of MRSA biofilm [8]. Hence, develop-
ment of anti-biofilm agents that interfere with steps in-
volved in biofilm formation and disrupt PBP2a
expression would be a sensible approach in developing a
new adjunctive treatment for recalcitrant MRSA
infections.
In recent reviews, plants have been identified as new
sources of resistance-modifying agents based on their cap-
acity of producing vast classes of antibacterial compounds
[9-11]. Hence, a useful strategy in controlling MRSA infec-
tions is by identifying plant components that can inhibit
biofilm production. Acalypha wilkesiana Müll. Arg. be-
longing to the Euphorbiaceae family has been traditionally
utilized to treat bacterial and fungal infections, malaria,
and gastrointestinal problems [12,13]. Previously, we found
anti-MRSA and other biological activities from A. wilkesi-
ana extracts and 9EA-FC-B [14,15]. This study aimed to
investigate the effects of 9EA-FC-B on MRSA’s biofilm
mechanism.
Methods
Plant material, isolation of bioactive fractions and
determination of MIC
The plant material, A. wilkesiana was collected from Broga,
Selangor, Malaysia and identified by Dr Christophe Wiart
from the School of Pharmacy. Voucher samples was depos-
ited in the herbarium of Faculty of Science, University of
Nottingham Malaysia Campus and assigned as UNMC 9.
The dried and ground plant materials (3.6 kg – A. wilkesi-
ana whole plant) was subjected to sequential extraction
using n-hexane (He), followed by ethyl acetate (EA) and fi-
nally 95% ethanol (EtOH). Extraction with each solvent was
conducted by soaking the plant material in 10 L of the solv-
ent (24 hours × 3 times) at room temperature.
The fraction 9EA-FC-B was isolated using a combin-
ation of vacuum liquid chromatography and preparative
centrifugal thin layer chromatography (silica gel) using
the following solvent system as the eluent: He with in-
creasing amount of chloroform (CHCl3) and CHCl3 with
increasing amount of methanol [15].
MICs of 9EA-FC-B and ampicillin against MRSA
ATCC 43300 which was 3.00 mg/mL and 0.05 mg/mL
respectively were determined previously using broth
microdilution assay conducted at 35°C [15]. The strain
used for this study (ATCC 43300) is a clinical strain that
was found to be resistant to beta-lactam antibiotics
[16-18] and was confirmed to be carrying the SCCmec
type II chromosome with mecA gene regulator that is re-
sponsible for expression of PBP2a [3,19].Phytochemical and HPLC analysis
Phytochemical analysis of 9EA-FC-B was carried out ac-
cording to the methods described previously [20]. An ali-
quot of 9EA-FC-B (40 μL of 10 mg/mL) was analyzed by
C18-reversed phase HPLC using the following gradient
solvent system: 2 min at 10% acetonitrile (ACN)/miliQ
water (H2O); a linear gradient to 75% ACN/H2O over
12 min; isocratic at 75% for 10 min; a linear gradient to
100% ACN for 2 min; isocratic at 100% ACN for 4 min.
HPLC was performed on a Varian 940-LC system using a
reversed phase analytical column (Pursuit XRs C18, 4.6 ×
150 mm, 5 μm) with photodiode array (PDA) detection at
254 nm.
Bacterial strains and growth conditions
The bacterial strain used in this study was MRSA ATCC
43300. The strain was maintained on tryptic soy agar
(TSA) (Hi-Media, India) supplemented with 2% NaCl
(Merck, Germany). All the experiments were initiated
using fresh overnight cultures grown in tryptic soy broth
(TSB) (Hi-Media, India) containing 1% glucose (Merck,
Germany).
Preparation of test agents
Fraction 9EA-FC-B was dissolved in dimethyl sulfoxide
(DMSO) (Sigma, USA) at stock concentration of 100 mg/
mL. Further dilution was carried out using TSB and the
final concentration of DMSO in the media did not exceed
1%. DMSO did not exert effect in the testing system as
shown in our preceding work [15,21]. Ampicillin (Amresco,
USA) was prepared at 10 mg/mL in sterile distilled water.
Inhibition of biofilm production assay
This experiment was conducted according to Mataraci and
Dosler [17] with a slight modification. A 96-well microtiter
plate was prepared with 9EA-FC-B at the following con-
centrations: MIC (3.00 mg/mL), 1/2 × MIC (1.50 mg/mL),
1/4 × MIC (0.75 mg/mL), 1/8 × MIC (0.38 mg/mL), and
1/16 × MIC (0.19 mg/mL); and ampicillin at MIC
(0.05 mg/mL). Aliquot of MRSA suspension was diluted
with the media (TSB + 1% glucose) prior to the assay and
was added to these wells. Final inoculums size was 1 ×
105 CFU/ml in total volume of 200 μl in each well. The
plate was incubated for 24 h at 35°C. After incubation, the
wells were washed with physiological buffered saline (PBS)
solution and quantification of biofilm production was
established by crystal violet staining method [22]. Briefly,
the crystal violet staining method includes addition of 99%
methanol (200 μl, Fisher Scientific Chemicals, USA) into
each well for fixation of attached bacteria and followed by
removal of the solvent and drying of the microtiter plate.
Once dried, the wells of the microtiter plate were stained
with 0.1% crystal violet (v/v in water) for 5 mins. The ex-
cess stain was discarded and plates were air dried. The
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(Fisher Scientific Chemicals, USA). The optical density
(OD) was read at 595 nm using a multimode plate reader
(Varioskan Flash, Thermo Scientific, USA). Experiment
was done in triplicates on three separate occasions.
Microtiter attachment assay
The methods employed in this experiment have been de-
scribed previously [23]. A 96-well microtiter plate was
prepared with 9EA-FC-B and ampicillin at the same
concentrations as in the inhibition of biofilm assay (see
above). Aliquot of MRSA suspension was diluted with
the media (TSB + 1% glucose) prior to the assay and was
added to these wells. Final inoculums size was 1 ×
107 CFU/ml in total volume of 200 μl in each well. The
plate was incubated for 1 h at 35°C. Following incuba-
tion, the wells were washed with PBS and the percentage
of cell attachment was determined by the crystal staining
method described above [22]. Experiment was done in
triplicates on three separate occasions.
PBP2a latex agglutination test on MRSA Biofilm
Prior to the latex agglutination test, MRSA was cultured
in 50 mm diameter petri dishes in 10 mL of TSB + 1% glu-
cose supplemented with 9EA-FC-B with concentrations
ranging from 0.19-3.00 mg/mL and ampicillin at 0.05 mg/
mL. The petri dishes were incubated for 24 h at 35°C.
After incubation, the broth was carefully removed and
0.5 mL PBS was added to the petri dishes. Using a sterile
5 μl inoculating loop, the biofilm layer was scraped off just
to fill the internal diameter (gives approximately 1.5 ×
109 CFU/ml). The obtained bacterial biofilm was proc-
essed according to the manufacturer’s instructions on the
MRSA screening kit (Cat. no. DR900A Denka Seiken,
Japan) in order to detect the presence of PBP2a. Semi-
quantitative estimation of PBP2a production in biofilms
was done based on the protocols described in Zhao et al.
[24] in which the intensity of agglutination was observed
and scored between + and + + +, where the control latex
which showed no reactivity in the absence of PBP2a is
considered as “-”.Figure 1 HPLC chromatogram of 9EA-FC-B. HPLC analysis of 9EA-FC-B (
at 254 nm) showing the presence of multiple severely overlapped peaks.Statistical analysis
Results for biofilm attachment and inhibition assays were
shown as means ± standard deviation of three independent
experiments. A one-way analysis of variance with Bonfer-
roni multiple comparison tests was used to compare dif-
ference between the control and treated groups. A P value
of 0.001 was taken as statistically significant.
Results
Chemical characterization of fraction 9EA-FC-B
HPLC analysis revealed that 9EA-FC-B consisted of a com-
plex mixture of compounds (Figure 1). These compounds
were likely to be tannins, saponins, sterols/steroids, and gly-
cosides based on the qualitative phytochemical analysis.
Inhibition of MRSA biofilm production
9EA-FC-B was tested at concentrations ranging from
3.00 mg/mL to 0.19 mg/mL and ampicillin at 0.05 mg/
mL. The MICs against MRSA growth in planktonic state
for 9EA-FC-B and ampicillin were 3.00 mg/mL and
0.05 mg/mL, respectively [15]. Figure 2 shows the per-
centage of MRSA biofilm formation in the different
treatments. Generally, 9EA-FC-B exhibited appreciable
activity against MRSA biofilm formation at MIC level
with the biofilm formation reduced to just 18.44%. At
concentrations lower than the MIC of 9EA-FC-B (i.e.
1.5 mg/mL and 0.75 mg/mL), the biofilm formation was
reduced by more than 2-fold compared to control
MRSA. On the other hand, ampicillin at MIC (0.05 mg/
mL) reduced biofilm formation to 15.51%, comparable
to that observed for 9EA-FC-B.
Decreased cell-surface attachment
In order to elucidate the possible mechanism of 9EA-
FC-B, cell-surface attachment was studied where MRSA
cultures, treated either with ampicillin or 9EA-FC-B,
were incubated for an hour. Cultures treated with 9EA-
FC-B showed a concentration dependent reduction in
cell-surface attachment. Notably, in the case of 9EA-FC-
B at MIC, cell-surface attachment was markedly40 μL of 10 mg/mL, C18-reversed phase, 4.6 × 150 mm, 5 μm, detected
Figure 2 MRSA biofilm formation (%) in 9EA-FC-B treatments. Biofilm formation in microtiter plate wells containing 9EA-FC-B (mg/mL) at
different concentrations. Three wells were used for each treatment. Experiment is representative of 3 independent tests, and error bars indicate
the standard deviation. All difference between control and treated MRSA were statistically significant (*** -p < 0.001).
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ampicillin (62.20%) (Figure 3).
Inhibition of PBP2a in MRSA biofilm
PBP2a latex agglutination test was conducted to measure
semi-quantitatively the amount of the resistant protein,
PBP2a found in the biofilm. A higher intensity of agglutin-
ation observed essentially corresponds to a higher level of
PBP2a found in the biofilm. MRSA control showed a mod-
erate intensity of agglutination while ampicillin treatmentFigure 3 Attachment of MRSA cells (%) to microtiter plate surface. At
(mg/mL) at different concentrations. Three wells were used for each treatm
indicate the standard deviation. All difference between control and treatedappeared to increase the amount of PBB2a in the biofilm.
However, no PBP2a was detected for treatments with 9EA-
FC-B at 3.00 mg/mL and 1.50 mg/mL (Table 1 and
Figure 4).
Discussion
In recent years, compound mixtures extracted from me-
dicinal plants have demonstrated anti-biofilm activities
against several virulent pathogens [25-27]. We have
shown in this study that 9EA-FC-B exhibited potentialtachment of MRSA cells in microtiter plate wells containing 9EA-FC-B
ent. Experiment is representative of 3 independent tests, and error bars
MRSA were statistically significant (***-p < 0.001).






3.00 1.50 0.75 0.38 0.19
Intensity of PBP2a Agglutination + + + + + - - + + +
Intensity of agglutination was observed and scored between + and + + +, where the control latex which showed no reactivity in the absence of PBP2a is
considered as “-” (interpretation: + + + strong presence of agglutination, + + agglutination against turbid background, + slight agglutination against turbid
background, − no agglutination).
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To further support the anti-MRSA effects of this plant
we have reported on the effectiveness of this fraction to
reverse ampicillin resistance by suppressing PBP2a ex-
pression [15]. Our earlier study has reported the non
toxic effects of this plant against normal cell lines
[14,28]. Therefore, suggesting that the components de-
rived from this plant have specific toxicity against bac-
terial cells and cancer cells [28].
HPLC analysis revealed that fraction 9EA-FC-B is a
complex mixture of plant metabolites, while phytochem-
ical analysis showed a higher presence of tannins in the
fraction compared to other phytochemicals (results not
shown). This was corroborated by another group that
previously reported the isolation of corilagin, geraniin
and ellagitannin from the same plant and these tannin
compounds demonstrated anti-staphylococcal activity. It
was proposed that these tannins exert their antibacterial
effects by causing cell wall damage which eventually re-
sults in cell lysis [29]. Besides, tannins were reported to
be capable of binding to peptidoglycan and destroy the
bacterial cell wall integrity [24]. The weaken cell integ-
rity may hinder the initial phase of biofilm production
that is the interaction between the bacterial cell wall and
the surface [30-32]. It is therefore highly plausible that
the occurrence of tannins in 9EA-FC-B was responsible
for a strikingly reduced MRSA cell-surface attachment
which was not observed in the ampicillin treated cul-
tures. Since attachment of bacterial cells to the surface
of its growth vessel influences the final mass of biofilm
production, a reduced cell-surface attachment at the ini-
tial stage reduces the number of bacteria involved in
biofilm development and production [23]. As such,Figure 4 Results of PBP2a latex agglutination test on MRSA biofilms.
according to the manufacturer’s guidelines. Shown are MRSA biofilm samp
ampicilin (0.05 mg/mL), which had moderate and strong agglutination, res
cultures treated with 9EA-FC-B at these concentrations; 0.19 mg/mL, 0.38 m
agglutination with turbid background. The middle disk is of biofilm sample
no agglutination.prevention of cell-surface attachment by 9EA-FC-B was
thought to have reduced MRSA biofilm formation. This
was entirely consistent with the results from the inhib-
ition of biofilm production assay that showed 9EA-FC-B
inhibited biofilm formation.
Ampicillin on the other hand, was found to suppress
MRSA biofilm formation comparable to the effect dis-
played by MIC of 9EA-FC-B. However, its inability to
prevent cell-surface attachment within one hour of incu-
bation in the microtiter attachment assay implied a pos-
sible delayed in its antibacterial action. Based on earlier
reports, a delayed antimicrobial action contributes to
prolonged and repeated exposure of MRSA to the anti-
microbial agent which in return results in emergence of
increased resistance [17,33]. This was further supported
by our data from the PBP2a latex agglutination assay,
which showed a higher level of PBP2a in the biofilms
isolated from the MRSA cultures that were treated with
ampicillin compared to the untreated control and those
treated with 9EA-FC-B. Further support was provided
by our recent finding based on Western blot experi-
ments that showed treatment of MRSA cultures with
ampicillin amplifies PBP2a expression in these bacterial
cells [15].
Results of the semi-quantitative analysis of PBP2a latex
agglutination test revealed that 9EA-FC-B reduced
PBP2a level in MRSA biofilms. Earlier, we have demon-
strated that 9EA-FC-B attenuated the level of PBP2a in
MRSA based on Western blot experiments [15]. It was
previously suggested that PBP2a mediates biofilm pro-
duction in MRSA, while the altered cell wall structure of
MRSA that expresses PBP2a promotes cell-cell interac-
tions [8]. Although the mechanism by which PBP2aA PBP2a latex agglutination test was performed and interpreted
les from an untreated control MRSA and culture treated with MIC
pectively. The three disks from right are of biofilms samples from
g/mL and 0.75 mg/mL (as indicated) showing a very weak
from culture treated with MIC 9EA-FC-B (3.00 mg/mL) is showing
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is known that cell-cell interaction is an important step
in multilayer structure assembly in the development of
biofilm [8,33]. Therefore, we propose that reduction of
PBP2a level by 9EA-FC-B adversely affected cell-cell
interaction and this, leads to a disruption in biofilm
production.
Conclusions
In summary, we have demonstrated that 9EA-FC-B af-
fected the production of MRSA biofilm by preventing
initial cell-surface attachment, disruption the cell-cell
interaction and reducing the PBP2a concentration in the
matrix. In addition to inhibiting the expression of PBP2a
by 9EA-FC-B [15], the anti-biofilm activity of 9EA-FC-B
represents another mechanism by which the fraction ex-
erts its anti-MRSA action. Finally, the occurrence of tan-
nins in 9EA-FC-B is postulated to be responsible for the
observed anti-biofilm activity.
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